AGT and cardiac hypertrophy: Our results showed that the administration of PR-957 specifically reduced chymotrypsin-like activity and blocked PTEN degradation, resulting in the prevention of hypertrophic remodeling including cardiac hypertrophy, fibrosis, and inflammation in mice after 2-week Ang II infusion (Figure 6).